Kinstellar advises TEVA on the USD 40.5 billion global acquisition of Actavis Generics
October 2016 – Kinstellar has advised its client TEVA, the world’s largest generic drug company by sales, on the Bulgarian, Czech, Hungarian and Slovak aspects of its USD 40.5 billion global acquisition of Actavis Generics, the generics division of Allergan. The deal combines two leading generics businesses with complementary strengths, particularly with respect to product pipelines and portfolios in these respective markets.
Lukáš Ševčík, Partner and head of the firm-wide M&A practice adds: ''Teva is one of the largest and most successful pharmaceutical companies in the world and this acquisition will strengthen its competitive position even further. We are honoured to have worked for such a prestigious company on several projects in our region, which has allowed us to showcase our diverse competences. Cross-border matters of this kind play to Kinstellar’s strengths, combining our geographic reach and strong sector focus.’’
Anthony O’Connor, Partner, head of Corporate M&A at Kinstellar Budapest and firm-wide co-head of the firm’s Private Equity team, comments: “Kinstellar is delighted to have advised our valued client TEVA on such a landmark transaction. The firm’s regional strength, combined with our strong M&A and pharma offering, has positioned us well to support TEVA as it reinforces and accelerates its corporate strategy.”
The Kinstellar team was: Partner Anthony O’Connor, Counsel Ákos Nagy, Associates Eszter Takácsi-Nagy, Ferenc Dávid, Junior Associates Áron Barta, Evelin Szőke and Barnabás Sági in Budapest; Partner Roman Oleksik and Counsel Zuzana Hodonova in Bratislava; Partner Jitka Logesova, Managing Associate Petr Holub in Prague; Partner Diana Dimova, Counsel Dessislava Fessenko, Managing Associates Nina Tsifudina and Svilen Issaev, Associates Plamena Deliyska, Vanya Shubelieva, Vladimir Sotirov, Mileslava Bogdanova and Stiliyana Ivanova in Sofia.